Palbociclib plus letrozole as first-line therapy in estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer with extended follow-up

Purpose In the initial PALOMA-2 (NCT01740427) analysis with median follow-up of 23 months, palbociclib plus letrozole significantly prolonged progression-free survival (PFS) in women with estrogen receptor-positive (ER+)/human epidermal growth factor receptor 2-negative (HER2−) advanced breast cance...

Full description

Saved in:
Bibliographic Details
Published in:Breast cancer research and treatment 2019-04, Vol.174 (3), p.719-729
Main Authors: Rugo, H. S., Finn, R. S., Diéras, V., Ettl, J., Lipatov, O., Joy, A. A., Harbeck, N., Castrellon, A., Iyer, S., Lu, D. R., Mori, A., Gauthier, E. R., Bartlett, C. Huang, Gelmon, K. A., Slamon, D. J.
Format: Article
Language:English
Subjects:
Analysis
Antineoplastic agents
Breast cancer
Cancer research
Care and treatment
Chemotherapy
Clinical Trial
Corporate sponsorship
Epidermal growth factor
Epidermal growth factors
ErbB-2 protein
Estrogen receptors
Estrogens
Medical schools
Medicine
Medicine & Public Health
Menopause
Oncology
Palbociclib
Patients
Phenols (Class of compounds)
Postmenopausal women
Quality of life
Safety
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Purpose In the initial PALOMA-2 (NCT01740427) analysis with median follow-up of 23 months, palbociclib plus letrozole significantly prolonged progression-free survival (PFS) in women with estrogen receptor-positive (ER+)/human epidermal growth factor receptor 2-negative (HER2−) advanced breast cancer (ABC) [hazard ratio (HR) 0.58; P  
ISSN:0167-6806
1573-7217
DOI:10.1007/s10549-018-05125-4